SUBSCRIBE
SUBSCRIBE
News   Deals

Sanofi-Aventis (France) Owners Oppose Big Hike To $19B Genzyme Corporation Bid

August 3, 2010 | 
1 min read
LONDON, Aug 3 (Reuters) - Sanofi-Aventis (SASY.PA) chief Chris Viehbacher should avoid paying much more than about $70 per share, or a total of $19 billion, to land U.S. biotech group Genzyme (GENZ.O), shareholders in the French group say.
Mergers & acquisitions Europe
Sanofi (France)
MORE ON THIS TOPIC
Creative collage illustration of financial business. Two businessmen shaking hands for partners agreement. Conceptual illustration of success deal, corporate ethic, connection.
Mergers & acquisitions
Merck, AstraZeneca Cancer Collaborator Gets Swallowed Up by Sino Biopharm
July 16, 2025
 · 
1 min read
 · 
Tristan Manalac
AbbVie's office in South San Francisco, California
Cancer
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B
July 10, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
A hand in a medical or laboratory glove holds a laboratory flask with coins with dollar sign. Investments in laboratory research and science. Concept of profit, making money, business. Modern design. Copy space.
Gene therapy
AstraZeneca Gains More Gene Therapy AAVs in JCR Deal Worth up to $825M
July 9, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Big fish with dollar sign eating many small ones. Competition, merger, business, monopoly concept. EPS 8 vector illustration, no transparency
M&A
Merck Makes Big Respiratory Play With $10B Acquisition of Verona
July 9, 2025
 · 
2 min read
 · 
Tristan Manalac